Shield Therapeutics plc (LON:STX – Get Free Report)’s share price was down 11.5% during trading on Tuesday . The company traded as low as GBX 5.19 and last traded at GBX 5.40. Approximately 11,462,072 shares traded hands during trading, an increase of 382% from the average session volume of 2,379,675 shares. The stock had previously closed at GBX 6.10.
Shield Therapeutics Price Performance
The stock’s 50 day moving average is GBX 5.38 and its two-hundred day moving average is GBX 7.08. The stock has a market capitalization of £57.75 million, a PE ratio of -2.70 and a beta of 1.72. The company has a debt-to-equity ratio of -146.28, a current ratio of 0.75 and a quick ratio of 2.16.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Read More
- Five stocks we like better than Shield Therapeutics
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
